2024-11-05 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Analysis

**1. Performance Overview**

Intuitive Surgical Inc. (ISRG) is a company that designs, manufactures, and sells minimally invasive surgical systems and instruments. It has shown significant outperformance compared to the S&P 500 (VOO) with a cumulative return of 365.06% compared to 131.28% for VOO. This translates to a current divergence of 233.78%, representing an 80.59% percentile based on historical data.

The company has exhibited strong alpha and beta values across different years, indicating consistent outperformance and higher volatility than the market. 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|------|
| 2015 | 3.9% | 16.7% | 4.7% | 0.8 |
| 2016 | 15.8% | 13.6% | 4.5% | 0.8 |
| 2017 | 70.6% | 10.4% | 51.9% | 0.9 |
| 2018 | 27.6% | 23.9% | 34.6% | 1.4 |
| 2019 | 26.9% | 21.4% | -1.8% | 1.4 |
| 2020 | 37.0% | 40.4% | 21.8% | 1.1 |
| 2021 | 34.7% | 16.1% | 6.0% | 1.4 |
| 2022 | -26.3% | 45.1% | -6.3% | 1.4 |
| 2023 | 27.0% | 21.4% | 2.2% | 1.2 |
| 2024 | 53.3% | 6.9% | 32.6% | 1.1 |

This analysis highlights ISRG's consistently strong performance and its higher sensitivity to market movements. 

**2. Recent Price Movement**

* Closing price: 507.42
* 5-day moving average: 509.54
* 20-day moving average: 500.39
* 60-day moving average: 488.84

ISRG currently trades slightly below its 5-day moving average, suggesting potential short-term downward pressure. However, the stock is above both its 20-day and 60-day moving averages, indicating positive longer-term momentum. 

**3. Technical Indicators**

* RSI: 67.25 (Oversold) -  This indicates potential short-term overbought conditions, suggesting a potential pullback may be in the near future.
* PPO: -0.06 (Neutral) - This indicates that the current momentum is neutral, not confirming any significant price trend.
* Delta_Previous_Relative_Divergence: 8.74 (+) -  This positive trend suggests that ISRG has been outperforming its recent 20-day average performance.
* Expected Return: 12.55% -  This indicates that the stock is expected to outperform the S&P 500 by 12.55% over the long term (2 years or more) in a long-term accumulation strategy.

**4. Recent Earnings Performance**

| Date | EPS | Revenue |
|---|---|---|
| 2024-10-18 | 1.59 | 2.04 B$ |
| 2024-07-19 | 1.48 | 2.01 B$ |
| 2024-04-19 | 1.54 | 1.89 B$ |
| 2023-10-20 | 1.18 | 1.74 B$ |
| 2024-10-18 | 1.18 | 1.74 B$ |

ISRG continues to demonstrate consistent revenue growth, with the most recent quarter (2024-10-18) exceeding analysts' expectations. This positive trend suggests that ISRG is well positioned to continue its growth trajectory.

**5. Financial Information**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-09-30  | $2.04B  | 67.41% |
| 2024-06-30  | $2.01B  | 68.30% |
| 2024-03-31  | $1.89B  | 65.87% |
| 2023-12-31  | $1.93B  | 66.24% |
| 2023-09-30  | $1.74B  | 66.94% |

The company maintains a strong and stable profit margin, demonstrating efficient operations and financial health.

**Capital and Profitability:**

| Quarter  | Equity   | ROE |
|---|---|---|
| 2024-09-30 | $15.58B | 3.63% |
| 2024-06-30 | $14.71B | 3.58% |
| 2024-03-31 | $13.96B | 3.90% |
| 2023-12-31 | $13.31B | 4.56% |
| 2023-09-30 | $12.54B | 3.32% |

ISRG boasts a healthy equity position and a generally consistent ROE, indicating efficient capital management and returns on investment.

**6. News & Recent Issues**

* **Recent Earnings:** ISRG's recent earnings report (2024-10-18) surpassed analyst expectations, with the company reporting strong revenue growth and exceeding its own projected revenue range. 
* **Market Outlook:**  The company is expected to continue its growth in the coming years, driven by the increasing adoption of robotic-assisted surgery and the growing demand for minimally invasive procedures. 
* **Analyst Opinions:** Analysts remain optimistic about ISRG's future prospects, with many rating the stock as a "Buy" or "Strong Buy."

**7.  Overall Analysis**

ISRG has proven to be a consistent outperformer, demonstrating strong financial performance, robust profitability, and a positive outlook for the future. The stock may experience short-term volatility due to its relatively high beta value and potential overbought conditions, but its long-term potential remains attractive, particularly for investors seeking exposure to the growing surgical robotics market. The expected return of 12.55% over the long term makes ISRG a promising option for a long-term accumulation strategy. 

**Disclaimer: This is not financial advice, and you should consult with a financial professional before making any investment decisions.** 
